Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study.,Journal of Diabetes Investigation

当前位置： X-MOL 学术 › J. Diabetes Investig. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study.
Journal of Diabetes Investigation ( IF 3.1 ) Pub Date : 2020-03-27 , DOI: 10.1111/jdi.13240
Daisuke Suzuki ₁ , Hodaka Yamada ₁ , Masashi Yoshida ₁ , Shunsuke Funazaki ₁ , Misato Amamoto ₁ , Jun Morimoto ₁ , Kazuo Hara ₁

Affiliation

Studies have shown that sodium–glucose cotransporter 2 (SGLT2) inhibitors increased time‐in‐range (TIR; percentage of time glucose level remains between 3.9 and 10.0 mmol/L [70–180 mg/dL]) and decreased glycemic variability in patients with type 1 diabetes. The aim of this study was to investigate the effects of SGLT2 inhibitors on TIR, glycemic variability and glucose control in Japanese patients with type 1 diabetes in a real clinical setting.

中文翻译：

钠-葡萄糖协同转运蛋白 2 抑制剂可改善日本 1 型糖尿病患者的时间范围而不增加低血糖：一项回顾性、单中心、试点研究。

研究表明，钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂可增加患者的时间范围（TIR；血糖水平保持在 3.9 至 10.0 mmol/L [70-180 mg/dL] 之间的时间百分比）并降低血糖变异性患有 1 型糖尿病。本研究的目的是在真实的临床环境中调查 SGLT2 抑制剂对日本 1 型糖尿病患者的 TIR、血糖变异性和血糖控制的影响。

更新日期：2020-03-27

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11